Abiraterone acetate + Prednisone or Prednisolone

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

Castrate Sensitive Prostate CancerMetastatic CancerMetastatic ER+ Her2- Breast CancerPostmenopausalProstate Cancer

Phase 2

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

CompletedNCT01381874

Janssen Research & Development, LLCMetastatic ER+ Her2- Breast Cancer, Postmenopausal

Start: 2011-08-24End: 2018-08-08Updated: 2019-04-11

Unknown Phase

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

RecruitingNCT06652607

Fondazione Policlinico Universitario Agostino Gemelli IRCCSCastrate Sensitive Prostate Cancer, Metastatic Cancer, Prostate Cancer

Start: 2024-12-20End: 2028-04-30Target: 152Updated: 2025-03-12

Related Papers

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.

2015-10-2649 citations

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology2014-05-2013 citations

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

Journal of Clinical Oncology2014-05-201 citations